AC Immune SA (ACIU) Stock Price

ACIUStock

$2.39−19.26%52W

Market Cap$237.63M

P/E—

PEG Ratio—

Div yield—

Beta1.59

ACIU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-34.98%

Price vs S&P 500 (4W)-8.66%

VGM Score54.88

P/CF (Annual)3.38x

Book Value / Share (Quarterly)$0.42

P/TBV (Annual)3.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.88%

Cash Flow / Share (Quarterly)$-0.61

Price vs S&P 500 (YTD)-35.81%

Net Profit Margin (TTM)-246.49%

EPS (TTM)$-0.52

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-0.52

Revenue Growth (5Y)-25.34%

EPS (Annual)$-0.85

ROI (Annual)-142.53%

Net Profit Margin (5Y Avg)-948.37%

Cash / Share (Quarterly)$0.90

Revenue Growth QoQ (YoY)1057.20%

ROA (Last FY)-45.67%

Revenue Growth TTM (YoY)-39.45%

EBITD / Share (TTM)$-0.32

ROE (5Y Avg)-61.88%

Operating Margin (TTM)-252.18%

Cash Flow / Share (Annual)$-0.84

P/B Ratio5.70x

P/B Ratio (Quarterly)5.68x

Net Income / Employee (Annual)$-700,206

EV / Revenue (TTM)10.10x

Net Interest Coverage (TTM)-61.40x

ROA (TTM)-28.13%

EV / EBITDA (TTM)3.82x

EPS Incl Extra (Annual)$-0.85

Current Ratio (Annual)1.02x

Quick Ratio (Quarterly)0.89x

3-Month Avg Trading Volume0.22M

52-Week Price Return-19.26%

EV / Free Cash Flow (Annual)3.05x

Revenue / Employee (TTM)$174,021

Tangible BV / Share (Quarterly)$0.15

P/S Ratio (Annual)56.10x

Asset Turnover (Annual)0.02x

52-Week High$4.85

Operating Margin (5Y Avg)-941.52%

EPS Excl Extra (Annual)$-0.85

CapEx CAGR (5Y)-12.05%

Tangible BV CAGR (5Y)0.30%

26-Week Price Return-25.08%

Quick Ratio (Annual)0.98x

13-Week Price Return8.64%

Total Debt / Equity (Annual)0.10x

Current Ratio (Quarterly)0.93x

Enterprise Value$214.37M

Revenue / Share Growth (5Y)-30.20%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-31.83%

Revenue / Employee (Annual)$35,532

Pretax Margin (Annual)-1971.65%

Cash / Share (Annual)$1.09

3-Month Return Std Dev54.81%

Net Income / Employee (TTM)$-429,049

ROE (Last FY)-156.95%

Net Interest Coverage (Annual)-18.84x

EPS Basic Excl Extra (Annual)$-0.85

P/FCF (TTM)2.52x

Receivables Turnover (TTM)3.29x

Total Debt / Equity (Quarterly)0.12x

EPS Incl Extra (TTM)$-0.52

Receivables Turnover (Annual)4.90x

ROI (TTM)-90.08%

P/S Ratio (TTM)11.45x

Pretax Margin (5Y Avg)-947.84%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$0.75

Free OCF CAGR (5Y)4.12%

Price vs S&P 500 (52W)-34.79%

Year-to-Date Return-23.89%

5-Day Price Return-2.45%

EPS Normalized (Annual)$-0.85

ROA (5Y Avg)-32.68%

Net Profit Margin (Annual)-1971.65%

Month-to-Date Return-8.78%

Cash Flow / Share (TTM)$-0.84

EBITD / Share (Annual)$-0.80

Operating Margin (Annual)-1940.05%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-58.22%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.52

P/TBV (Quarterly)19.88x

P/B Ratio (Annual)5.70x

Pretax Margin (TTM)-246.49%

Book Value / Share (Annual)$0.54

Price vs S&P 500 (13W)5.95%

Beta1.59x

P/FCF (Annual)3.07x

Revenue / Share (TTM)$0.20

ROE (TTM)-99.20%

52-Week Low$2.54

vGradeC

gGradeC

mGradeB

vgmGradeC

ACIU Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.14	$0.02	+117.75%(+$0.16)
Q1 2026	Apr 30, 2026	-$0.17	-$0.18	-7.14%(-$0.01)
Q4 2025	Mar 13, 2026	-$0.20	-$0.17	+17.10%(+$0.04)
Q3 2025	Nov 4, 2025	-$0.21	-$0.19	+7.78%(+$0.01)
Q2 2025	Aug 5, 2025	-$0.20	-$0.25	-29.23%(-$0.06)

ACIU Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.40

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ACIUAC Immune SA	C	C	B	11.4x	-39.5%	—	—	$2.39
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases caused by protein misfolding. The company uses proprietary technology platforms to develop small molecules, antibodies, and vaccines for both therapeutic and diagnostic applications. Its pipeline includes clinical-stage candidates such as Crenezumab and Semorinemab.